Brachytherapy

Papers
(The TQCC of Brachytherapy is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
PPP03 Presentation Time: 10:48 AM39
BP02 Presentation Time: 4:09 PM26
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM21
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM18
PHSOR06 Presentation Time: 9:25 AM17
PO042516
PO032416
MPP02 Presentation Time: 4:09 PM16
BP08 Presentation Time: 5:03 PM15
PPP02 Presentation Time: 10:39 AM15
PO022715
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po14
PO041714
Evaluation of variability in applicator position and organs at risk dose in fractionated intracavitary brachytherapy for cervical cancer13
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy12
GPP03  Presentation Time: 9:33 AM12
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data12
P010511
Editorial Board11
PHSOP2  Presentation Time: 9:05 AM11
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost11
PSOR03  Presentation Time: 12:10 PM10
PSOR12  Presentation Time: 5:25 PM10
PO3510
PSOR8  Presentation Time: 12:05 PM10
PO9310
Editorial Board10
PO4710
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy9
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications9
Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis9
PO04219
PO02499
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study9
PPP04  Presentation Time: 10:57 AM8
MSOR11 Presentation Time: 8:50 AM8
Author Index8
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma8
PO02348
PRPP05  Presentation Time: 11:06 AM8
P03018
PL02 Presentation Time: 1:45 PM8
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients8
Determination of the optimal time for planning SAVI brachytherapy for APBI7
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life7
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM7
GSOR14  Presentation Time: 11:35 AM7
MSOR12 Presentation Time: 8:55 AM7
The case for risk-stratified IORT for early breast cancer7
PO107
Table of Contents7
Masthead7
Partial breast irradiation: An updated consensus statement from the American brachytherapy society7
PO46  Presentation Time: 4:45 PM7
PP02  Presentation Time: 9:10 AM6
PHSOR04  Presentation Time: 12:45 PM6
PP05  Presentation Time: 5:06 PM6
PO206
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer6
Table of Contents6
MSPP03  Presentation Time: 4:20 PM6
PSOR02  Presentation Time: 4:35 PM6
PO216
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma6
PHSOR05  Presentation Time: 12:50 PM6
GSOR04  Presentation Time: 12:15 PM6
PL02  Presentation Time: 1:45 PM6
High-dose-rate brachytherapy for airway malignancy a single institution experience6
Masthead6
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up5
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes5
PO1145
Skin Posters PO07015
PO01195
American Brachytherapy Society (ABS) rectoprostatic gel spacer consensus statement5
Quantifying geometric and dosimetric advantage from the use of rectal spacing in HDR prostate brachytherapy5
PO02415
PO01095
PSOR02 Presentation Time: 11:35 AM5
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?5
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
PO04245
PO02425
PO914
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction4
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
PLANER: Development and validation of a real-time image-guided dynamic dosimetric framework for I-125 seed brachytherapy4
MSOP03  Presentation Time: 8:10 AM4
PP02  Presentation Time: 10:09 AM4
PHSOR06  Presentation Time: 12:55 PM4
Comment on “How accurate is applicator reconstruction in HDR gynecological brachytherapy? Patient-specific results from an electromagnetic tracking system designed to intercept errors before radiation4
GSOR13  Presentation Time: 12:30 PM4
Comment on “high-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement”4
Improving complex brachytherapy efficiency: Multidisciplinary quality assurance and workflow optimization4
Randomized trial comparing hypnosis versus standard management on patient anxiety and pain during pelvic brachytherapy applicator removal4
Is single implant and multiple fractions radio-biologically iso-effective for cervical cancer high-dose-rate brachytherapy: Observation from patient cohorts during COVID pandemic4
MPP02  Presentation Time: 4:09 PM4
PO154
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle4
PO194
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy4
Development of a dosimetric phantom using OSLDs or TLD-100 for external audits of high-dose-rate 192Ir brachytherapy sources: Preliminary results4
Editorial Board4
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy4
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review4
MSOP06  Presentation Time: 8:25 AM4
GPP06  Presentation Time: 11:15 AM4
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM4
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT4
GSOR09 Presentation Time: 12:10 PM3
P03043
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology3
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent3
Dosimetric characterization and experimental validation for a low-kV FPXS electronic brachytherapy system3
PRSOP08  Presentation Time: 12:05 PM3
PO523
MSOR11 Presentation Time: 5:50 PM3
PP04  Presentation Time: 9:47 AM3
PP05  Presentation Time: 11:36 AM3
PO533
PSOR7  Presentation Time: 12:00 PM3
PO33  Presentation Time: 10:30 AM3
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM3
Patterns of anesthesia(AS) and analgesia(AG) practice in gynecological brachytherapy in India3
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer3
PRPP02  Presentation Time: 10:39 AM3
PO02203
PO01103
PRSOP03  Presentation Time: 11:40 AM3
PO863
PO40  Presentation Time: 4:45 PM3
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
PSOR3  Presentation Time: 11:40 AM3
PO02613
PO03203
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer3
Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma3
GPP04  Presentation Time: 9:42 AM3
PPP05 Presentation Time: 11:06 AM3
A novel dose-based intra-preplan method for high-dose-rate brachytherapy in cervical cancer using modeling and optimization algorithms3
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer3
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting3
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital2
Table of Contents2
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada2
MSOR7 Presentation Time: 5:30 PM2
GSOR06 Presentation Time: 5:25 PM2
Accelerated partial breast irradiation with high-dose-rate multicatheter brachytherapy: 30-year results of a phase 2 clinical trial2
Masthead2
Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center2
MSPP05  Presentation Time: 4:40 PM2
GSOR02  Presentation Time: 11:35 AM2
MSS11  Presentation Time: 4:35 PM2
GSOR12 Presentation Time: 5:55 PM2
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook2
PO03142
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry2
Table of Contents2
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)2
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer2
PO02332
Development of a phantom and analysis of brachytherapy dosimetry using the sulfamic acid/electron paramagnetic resonance system2
PO822
GSOR10 Presentation Time: 12:15 PM2
GSOR20  Presentation Time: 12:05 PM2
Masthead2
PO02292
PO03112
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method2
PO122
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
PP04  Presentation Time: 11:27 AM2
P01142
GYN Posters PO012
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
Table of Contents2
PL03 Presentation Time: 2:00 PM2
PO322
PO03102
PO492
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
PHSOP6  Presentation Time: 9:25 AM2
Rule-based AI automated adaptive treatment planning for image guided cervical cancer brachytherapy2
PO102
PP02  Presentation Time: 8:29 AM2
PSOR06  Presentation Time: 12:25 PM2
PO04082
Letter to the editor regarding “Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy”2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer2
PO02582
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien2
PHSOR08  Presentation Time: 1:05 PM2
Combined operative and radiotherapeutic treatment for locally recurrent gynaecologic cancer with pelvic wall invasion: A monocentric retrospective study2
PO27  Presentation Time: 7:40 AM2
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy2
Actinium-225 Targeted Agents: Where Are We Now?2
PO01112
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment2
Systematic review of brachytherapy for symptom palliation2
GSOR06  Presentation Time: 11:55 AM2
MPP05  Presentation Time: 4:36 PM2
PO04282
Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer2
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy2
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward2
Effect of radiation dosage to vital ocular structures on visual outcomes: Re-evaluation for the future2
PO042
MSOR9 Presentation Time: 5:40 PM2
PL04  Presentation Time: 2:15 PM2
PO171
PO02631
Mortality and postinterventional complications after ablative treatment of liver malignancies: A cohort study of 4374 patients1
MSS04  Presentation Time: 4:00 PM1
PO111
Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy1
Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-1031
MSOR10 Presentation Time: 8:45 AM1
Masthead1
Sunday, June 19, 2022 10:30 AM - 11:30 AMPP07  Presentation Time: 10:30 AM1
Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retr1
PO28  Presentation Time: 7:40 AM1
PO051
Saturday, July 13, 202411:30 AM - 12:30 PMPSOR01 Presentation Time: 11:30 AM1
Prostate Posters PO04011
A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques1
Table of Contents1
Saturday, July 13, 20249:00 AM - 10:00 AMPHSOR01 Presentation Time: 9:00 AM1
PO03091
PO01161
PSOR12 Presentation Time: 12:25 PM1
PO1191
PO131
Long-term disease-free survival following salvage brachytherapy for recurrent pediatric rhabdomyosarcoma: Two case reports and review of relevant literature1
PO1061
MSOR7  Presentation Time: 5:15 PM1
PPP06 Presentation Time: 11:15 AM1
From patient to pioneer: The inspiring journey of Dr. Brian Moran1
Friday, June 17, 20222:30 PM - 3:30 PM PHSPP01  Presentation Time: 2:30 PM1
PO30  Presentation Time: 10:30 AM1
BP04 Presentation Time: 4:27 PM1
PO1031
PP04 Presentation Time: 4:27 PM1
Inter-observer effects in needle reconstruction for temporary prostate brachytherapy: Dosimetric implications and adaptive CBCT-TRUS registration solutions1
Re: Letter to the editor with regards to “Impact of detector selection on commissioning of Leipzig surface applicators with improving immobilization in high-dose-rate brachytherapy” by Li et al.1
PO1001
Therapeutic and prophylactic effects of radiation therapy in the management of recurrent granulation tissue induced tracheal stenosis: a review on the role of Endobronchial brachytherapy and external 1
GSOR05  Presentation Time: 12:20 PM1
Masthead1
0.58602905273438